+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Auditory musical hallucinations associated with extended-release pramipexole in an elderly patient with Parkinson's disease

Auditory musical hallucinations associated with extended-release pramipexole in an elderly patient with Parkinson's disease

Medicine 93(27): E251

Auditory musical hallucinations (AMHs) are rare complex auditory hallucinations in Parkinson's disease (PD) that have been limited previously. The characteristics of AMHs in PD remain uncertain. We describe a 72-year-old woman with PD who presented with AMHs. The AMHs occurred after immediate-release pramipexole was switched to extended-release pramipexole. The AMHs were a quiet piano or often songs on a loud radio or background music over other sounds. The music was unpleasant, but not objectionable, threatening, or ego-syntonic, and it did not interrupt her daily activities. AMHs in PD were non-threatening, and dopaminergic treatment may predispose patients to AMHs or be a unique possible cause of AMHs. The hallucinations can occur after immediate-release pramipexole was switched to extended-release pramipexole.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057267596

Download citation: RISBibTeXText

PMID: 25501095

DOI: 10.1097/md.0000000000000251

Related references

Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexole. Patient Preference and Adherence 6: 49-54, 2012

Pramipexole extended release: in Parkinson's disease. Cns Drugs 24(4): 327-336, 2010

Pramipexole extended release in Parkinson's disease. Expert Review of Neurotherapeutics 11(9): 1229-1234, 2012

Pramipexole and its extended release formulation for Parkinson's disease. Journal of Central Nervous System Disease 3: 169-178, 2011

Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease. Medicine 97(34): E11316, 2018

Pramipexole extended-release: a review of its use in patients with Parkinson's disease. Drugs 74(18): 2175-2190, 2015

Pramipexole extended release: a novel treatment option in Parkinson's disease. Parkinson's Disease 2010: 612619, 2011

Case history of a patient with musical hallucinations and Parkinson's disease. International Journal of Geriatric Psychiatry 13(12): 886-887, 1999

Elvis is back: musical hallucinations in a Parkinson disease patient. Southern Medical Journal 103(8): 837-841, 2010

Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease. Expert Opinion on PharmacoTherapy 11(13): 2221-2230, 2011

Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease. Movement Disorders 25(10): 1505-1506, 2010

Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 77(8): 767-774, 2011

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. Clinical Interventions in Aging 7: 83-88, 2012

Cost-Effectiveness Analysis of Pramipexole Extended Release Monotherapy In Early Parkinson`S Disease. Value in Health 18(7): A757, 2015

Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology 77(8): 759-766, 2011